Mon, Oct 20, 2014, 9:34 AM EDT - U.S. Markets close in 6 hrs 26 mins

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • Monza_F1 Monza_F1 Feb 7, 2008 11:28 PM Flag

    SNTA to head higher...

    1. Getting the word out. Safi has made the time to educate Wall Street. This continues with another conference (BIO..) next week.
    2. Large Hedge Fund exposure and low float - just look at the bid/ask and you can see how easy it is to move this stock.
    3. Company is holding an analyst day in NY at the end of March. Great timing as the news flow will begin to get interesting.
    4. Company has said to expect an update on Elesclomol at a conference in early summer - there is only one...ASCO. This stock will trade higher in anticipation of positive ASCO news.
    5. Additional milestone payments from GSK.
    6. Initiation of new trials against other forms of cancer susceptible to oxidative stress...prostate, breast, pancreatic just to name a few of the possibilities.
    7. End of 08 - trial enrollment completed and results released on secondary endpoint...primary endpoint will take roughly 12 months longer to obtain data (showing this company has the leadership and experience to position itself in the most favorable way and, by default, increase shareholder value).

    There is more but IMHO this in and of itself will move this stock another 50%+ this year.

    Remember, SNTA retains 40-50% royalties in the US on Elesclomol and double digit royalties ex-US.

    This is an exciting time to be a SNTA shareholder and at these prices I consider it a gift.

    Pls do your own DD. GL.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SNTA
3.01-0.02(-0.50%)9:34 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.